Evidence map›Paper›PMID 37495535›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Antiemetic Effect of Rikkunshito, a Japanese Kampo Herbal Medicine, on Cisplatin-induced Nausea and Vomiting: A Nationwide Database Study in Japan.

Taisuke Jo, Daisuke Shigemi, Takaaki Konishi, Hayato Yamana, Nobuaki Michihata, Ryosuke Kumazawa, Akira Yokoyama, Hirokazu Urushiyama, Hiroki Matsui, Kiyohide Fushimi and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Taisuke JoDepartment of Health Services Research, the University of Tokyo, Japan.
Daisuke ShigemiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan.
Takaaki KonishiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan.
Hayato YamanaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan.
Nobuaki MichihataDepartment of Health Services Research, the University of Tokyo, Japan.
Ryosuke KumazawaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan.
Akira YokoyamaDepartment of Respiratory Medicine, the University of Tokyo, Japan.
Hirokazu UrushiyamaDepartment of Respiratory Medicine, the University of Tokyo, Japan.
Hiroki MatsuiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan.
Kiyohide FushimiDepartment of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Japan.
Takahide NagaseDepartment of Respiratory Medicine, the University of Tokyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan.
The University of Tokyo · JPJichi Medical University · JPNational Center for Global Health and Medicine · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective The effect of Rikkunshito, a Japanese herbal Kampo medicine, on chemotherapy-induced nausea and vomiting (CINV) has been evaluated in several small prospective studies, with mixed results. We retrospectively evaluated the antiemetic effects of Rikkunshito in patients undergoing cisplatin-based chemotherapy using a large-scale database in Japan. Methods The Diagnosis Procedure Combination inpatient database from July 2010 to March 2019 was used to compare adult patients with malignant tumors who had received Rikkunshito on or before the day of cisplatin administration (Rikkunshito group) and those who had not (control group). Antiemetics on days 2 and 3 and days 4 and beyond following cisplatin administration were used as surrogate outcomes for CINV. Patient backgrounds were adjusted using the stabilized inverse probability of treatment weighting, and outcomes were compared using univariable regression models. Results We identified 669 and 123,378 patients in the Rikkunshito and control groups, respectively. There were significantly fewer patients using intravenous 5-HT

Indexed as

AntiemeticsAntineoplastic AgentsDrugs, Chinese HerbalAdultCisplatinHumansJapanMedicine, KampoNauseaProspective StudiesRetrospective StudiesVomitingAntiemeticsAntineoplastic AgentsCisplatinDrugs, Chinese Herballiu-jun-zi-tangantiemeticscancerchemotherapyKamporeal-worldRikkunshito

Identifiers

PMID37495535
PMCPMC11045374
OpenAlexW4385236935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.